BioWorld

July 9, 2003

View Archived Issues

Killer Clots That Attack Heart, Brain Countered By Clot-Busting Drugs Linked To Red Blood Cells

Read More

XOMA Regains Full Rights To Neuprex As Baxter Pulls Out

Read More

AEterna To Raise C$35.6M Upon Entering Bought-Deal Agreement

Read More

Other News To Note

Read More

Amgen Files With FDA Seeking Approval Of Enbrel In Psoriasis

Amgen Inc.'s Enbrel could be the first TNF blocker to make it to market as a treatment for psoriasis, an inflammatory disease often mischaracterized as a disease of the skin. (BioWorld Today) Read More

Genentech's Avastin Rights Outside U.S. Go To Roche

Read More